State Street
DFTX

State Street’s Definium Therapeutics DFTX Stock Holding History

State Street’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144M Buy
3,065,390
+593,517
+24% +$14.7M ﹤0.01% 1265
2026
Q1 		$46.7M Buy
2,471,873
+103,807
+4% +$1.76M ﹤0.01% 1777
2025
Q4 		$31.7M Buy
2,368,066
+443,173
+23% +$5.48M ﹤0.01% 2002
2025
Q3 		$22.7M Buy
1,924,893
+119,000
+7% +$1.11M ﹤0.01% 2166
2025
Q2 		$11.7M Sell
1,805,893
-36,321
-2% -$239K ﹤0.01% 2494
2025
Q1 		$10.8M Buy
1,842,214
+60,715
+3% +$435K ﹤0.01% 2484
2024
Q4 		$12.4M Sell
1,781,499
-33,330
-2% -$229K ﹤0.01% 2498
2024
Q3 		$10.3M Buy
1,814,829
+9,782
+0.5% +$68K ﹤0.01% 2587
2024
Q2 		$13M Buy
1,805,047
+1,686,143
+1,418% +$14.7M ﹤0.01% 2407
2024
Q1 		$1.12M Sell
118,904
-3,200
-3% -$18.2K ﹤0.01% 3442
2023
Q4 		$447K Buy
122,104
+104
+0.1% +$313 ﹤0.01% 3661
2023
Q3 		$382K Hold
122,000
– – ﹤0.01% 3731
2023
Q2 		$436K Hold
122,000
– – ﹤0.01% 3723
2023
Q1 		$387K Buy
122,000
+23,099
+23% +$76.8K ﹤0.01% 3835
2022
Q4 		$218K Buy
98,901
+44,994
+83% +$125K ﹤0.01% 4064
2022
Q3 		$189K Sell
53,907
-10,280
-16% -$98.7K ﹤0.01% 4168
2022
Q2 		$616K Sell
64,187
-345,513
-84% -$4.37M ﹤0.01% 3757
2022
Q1 		$6.82M Buy
409,700
+27,784
+7% +$482K ﹤0.01% 3028
2021
Q4 		$7.91M Buy
381,916
+6,310
+2% +$201K ﹤0.01% 3031
2021
Q3 		$13.1M Buy
375,606
+77,275
+26% +$3.34M ﹤0.01% 2721
2021
Q2 		$15.4M Buy
+298,331
New +$15.7M ﹤0.01% 2653

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

State Street's DFTX Position: Q2 2026 in Review

State Street increased its Definium Therapeutics (DFTX) stake by 24% in Q2 2026, buying an estimated $14.7M and bringing the position to 3,065,390 shares worth $144M. The position accounts for ﹤0.01% of the portfolio, ranked #1265.

State Street first reported a position in DFTX in Q2 2021 and has held it in 21 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • State Street held 3,065,390 shares of Definium Therapeutics worth $144M as of Q2 2026.
  • State Street bought 593,517 Definium Therapeutics shares in Q2 2026, an estimated $14.7M.
  • Definium Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1265 holding.
  • State Street first reported a position in Definium Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.